Drug Search Results
More Filters [+]

Levobetaxolol

Alternative Names: levobetaxolol, betaxon
Latest Update: 2023-05-12
Latest Update Note: Clinical Trial Update

Product Description

Levobetaxolol is a cardioselective β-blocker that has been demonstrated to reduce intraocular pressure in patients affected with primary open-angle glaucoma and ocular hypertension. Levobetaxolol may be an effective neuroprotectant because of its great capacity to block sodium and calcium influx, which might confer a neuroprotective activity (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2704505/)

Mechanisms of Action: ADRB1 Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Approved

Approved Countries: India | Pakistan

Approved Indications: None

Known Adverse Events: None

Company: Alcon
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Levobetaxolol

Countries in Clinic: China

Active Clinical Trial Count: 1

Highest Development Phases

Phase 3: Glaucoma, Open-Angle|Hypertension

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

ZK-LBL-2016-01

P3

Completed

Hypertension|Glaucoma, Open-Angle

2021-07-01

95%

Recent News Events